The latest update is out from Galectin Therapeutics (GALT).
Galectin Therapeutics Inc. has elevated Dr. Khurram Jamil to the role of Chief Medical Officer, recognizing his extensive experience in the pharmaceutical industry. Dr. Jamil brings a wealth of knowledge from his time at Mallinckrodt Pharmaceuticals, where he spearheaded teams to U.S. and Japan drug approvals. An accomplished professional with 7 patents and over 40 published manuscripts, he is set to receive a competitive compensation package, including a $500,000 base salary and stock options. This appointment follows the resignation of the former Chief Medical Officer, Dr. Pol Boudes.
See more data about GALT stock on TipRanks’ Stock Analysis page.
